基本信息
浏览量:159
职业迁徙
个人简介
Robert Hills studied mathematics at the University of Oxford, where his DPhil was on exploration of symmetries with applications to superconductivity. He joined the CTSU in 1993 as a programmer on the QUASAR trial in colorectal cancer. Following a brief period working in low temperature physics at the University of Nottingham, he moved to the University of Birmingham Clinical Trials Unit (BCTU) in 1997.There, he worked on clinical trials in Acute Myeloid Leukaemia, Alzheimer’s Disease, women’s health and many others as well as large scale individual patient data meta-analyses of treatment for colorectal cancer.
In 2006, he moved to Cardiff University as statistical lead for the NCRI/MRC trials in Acute Myeloid Leukaemia. During his 12 years in Cardiff he was head of the Haematology Clinical Trials Unit, and latterly led on clinical cancer research methodology and haematological malignancies. The novel designs used in these trials allow the clinical value of disease monitoring to be evaluated, as well as numerous targeted therapies in designs that allow for an early change from an unpromising new therapy to one with greater potential. Additionally, he continued his work on the integration of laboratory and clinical data, and on individual patient data meta-analyses, where he demonstrated a survival benefit for gentuzumab ozogamicin in AML.
In 2006, he moved to Cardiff University as statistical lead for the NCRI/MRC trials in Acute Myeloid Leukaemia. During his 12 years in Cardiff he was head of the Haematology Clinical Trials Unit, and latterly led on clinical cancer research methodology and haematological malignancies. The novel designs used in these trials allow the clinical value of disease monitoring to be evaluated, as well as numerous targeted therapies in designs that allow for an early change from an unpromising new therapy to one with greater potential. Additionally, he continued his work on the integration of laboratory and clinical data, and on individual patient data meta-analyses, where he demonstrated a survival benefit for gentuzumab ozogamicin in AML.
研究兴趣
论文共 415 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
BRITISH JOURNAL OF HAEMATOLOGYno. 3 (2024): 871-876
Julia-Annabell Georgi, Sebastian Stasik,Michael Kramer,Manja Meggendorfer,Christoph Röllig, Torsten Haferlach,Peter Valk, David Linch,Tobias Herold, Nicolas Duployez,Franziska Taube, Jan Moritz Middeke,
HemaSphereno. S3 (2023): e345570d-e345570d
引用1浏览0引用
1
0
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): 503-503
引用2浏览0引用
2
0
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)
引用0浏览0引用
0
0
Adriane Halik,Marlon Tilgner,Patricia Silva, Natalia Estrada-Barreras, Robert Altwasser,Ekaterina Jahn, Michael Heuser,Hsin-An Hou,Marta Pratcorona,Robert Kerrin Hills,Klaus H. Metzeler,Laurene Fenwarth,
BLOODno. Supplement 1 (2023): 63-63
BLOODno. 20 (2023): 1697-1707
Endocrine Abstractsno. 10 (2023): 2615-2625
British journal of haematologyno. 2 (2023): 213-214
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn